CDKN2C
CDKN2C (Cyclin-dependent kinase 4 inhibitor C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Brain and spinal cord tumours and Burkitt lymphoma.
Overview
Interacts strongly with CDK6, weakly with CDK4. Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB.
Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes affected pathway 0.76, literature 0.94, genetic association 0.22, somatic mutation 0.80, animal model 0.76). IntOGen calls it a driver in 3 cohorts (2 activating, 1 loss-of-function), covering Burkitt Lymphoma, High-Grade Glioma, NOS, Low-Grade Glioma, NOS.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CDKN2C (Cyclin-dependent kinase 4 inhibitor C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Brain and spinal cord tumours and Burkitt lymphoma.
- 1 · What it is
CDKN2C (Cyclin-dependent kinase 4 inhibitor C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Brain and spinal cord tumours and Burkitt lymphoma.
- 2 · What goes wrong in cancer
Interacts strongly with CDK6, weakly with CDK4. Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB.
- 3 · How drugs use it
No product in this corpus aims at CDKN2C yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:1789 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P42773 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000123080 (association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: brain cancer 0.50 (GraphQL API, CC0)); IntOGen CDKN2C (driver in 3 cohorts (Act 2, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Interacts strongly with CDK6, weakly with CDK4. Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB. Locus 1p32.3 (HGNC).
- Brain and spinal cord tumours: Open Targets association 0.50 with brain cancer (MONDO_0001657)
- Burkitt lymphoma: IntOGen driver in 1 cohort (BL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: High-Grade Glioma, NOS; Low-Grade Glioma, NOS.
Latest papers
topQuery for this target: (TITLE:"CDKN2C" OR ABSTRACT:"CDKN2C" OR TITLE:"cyclin dependent kinase inhibitor 2C" OR ABSTRACT:"cyclin dependent kinase inhibitor 2C" OR TITLE:"Cyclin-dependent kinase 4 inhibitor C" OR ABSTRACT:"Cyclin-dependent kinase 4 inhibitor C" OR TITLE:"INK4C" OR ABSTRACT:"INK4C" OR TITLE:"p18" OR ABSTRACT:"p18") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDKN2C, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetID3
Shares Burkitt lymphoma, IntOGen, Open Targets Platform.
- TargetP2RY8
Shares Burkitt lymphoma, IntOGen, Open Targets Platform.
- TargetGNAI2
Shares Burkitt lymphoma, IntOGen.
- TargetTFAP4
Shares Burkitt lymphoma, IntOGen.
- TargetRFX7
Shares Burkitt lymphoma, Open Targets Platform.
- TargetPCBP1
Shares Burkitt lymphoma, IntOGen, Open Targets Platform.
- TargetSIN3A
Shares Burkitt lymphoma, IntOGen.
- TargetUSP7
Shares Burkitt lymphoma, IntOGen.